Arabic Arabic English English French French German German
dark

Lipocine’s LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study

Lipocine Inc. today announced positive topline 36-week results from its Phase 2 proof of concept LiFT (“Liver Fat intervention with oral Testosterone”) clinical study, NCT04134091, investigating LPCN 1144 in men with biopsy-confirmed NASH. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Report from the Annual General Meeting 2021 in Elekta

Next Post

Applied UV Declares Monthly Preferred Stock Dividend

Related Posts
Total
0
Share